BioMarin Pharmaceutical Inc. (BMRN) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash flow ⢠Healthy liquidity ⢠Premium valuation BMRN delivers strong cash generation and liquidity with solid but unspectacular profitability, while its premium valuation leaves limited margin of safety.
Price Behavior
Key Price Behavior Insights: ⢠Rebound off low ⢠Choppy recovery ⢠Needs breakout Support Level: $53.0-$53.3, deeper support at $50.0-$49.7 Resistance Level: $57.0-$57.3 BMRN has rebounded constructively over the last month from a mid-May low, but the move remains choppy and needs a clear break above $57.0-$57.3 while holding $53 to confirm a durable uptrend.
Sentiment & News
Key News Insights: ⢠Mixed trial readout ⢠VOXZOGO strength ⢠FDA filing catalyst BioMarin's May 2026 updates were mixed but leaned positive, as BMN 401 missed one key endpoint while VOXZOGO posted strong Phase 3 results that could support 2026 FDA filing plans and boost momentum.
AI Summary
BMRN has shifted from a speculative pipeline story to a cash-generative rare-disease platform with strong liquidity and multiple growth drivers, but at ~33.7x earnings the upside now hinges on VOXZOGO-led execution and clean clinical/regulatory delivery, so the stock looks investable only if growth continues to outpace the premium valuation.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |